Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by hockeylad33on Feb 28, 2012 7:12pm

259 Views

Post# 19601364

RE: RE: news !!!!

Back of the envelope calcualtion on Mani-1 recoverable reserves gives me about 400K boe. Assumptions:

75 acre closure, 20% porosity, 20 ft net pay, 20% recovery factor. Very ballpark, but certainly not a huge find. Hopefully this was already priced in by the big biys, but I have a sneaking suspicion we will see a sell-off tomorrow.

On the positive side, anticipated 350 acre closure at Flami-1.

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario